CancerDrs Find care

Brain Cancer clinical trials in Georgia

22 actively recruiting brain cancer trials at 7 sites across Georgia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Piedmont Hospital — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
  • WellStar Cobb Hospital — Austell, Georgia
Phase 3 Recruiting Academic/Other

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…

Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
  • Northside Hospital — Atlanta, Georgia
  • Northside Hospital-Cherokee — Canton, Georgia
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Georgia:
  • Children's Healthcare of Atlanta — Atlanta, Georgia
Phase 2, Phase 3 Recruiting Academic/Other

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …

Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Georgia:
  • Piedmont Atlanta Hospital — Atlanta, Georgia
  • Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 3 Recruiting Industry

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…

Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Sites in Georgia:
  • Children's Healthcare of Atlanta — Atlanta, Georgia
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

Sponsor: Hoffmann-La Roche
NCT ID: NCT05503264
Sites in Georgia:
  • Children's Healthcare of Atlanta Center for Advanced Pediatrics — Atlanta, Georgia
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Georgia:
  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah, Georgia
Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 2 Recruiting Industry

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…

Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Georgia:
  • Augusta University — Augusta, Georgia
Phase 1, Phase 2 Recruiting Academic/Other

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA ap…

Sponsor: Emory University
NCT ID: NCT04590664
Sites in Georgia:
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Network

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…

Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 1 Recruiting Academic/Other

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary…

Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04732065
Sites in Georgia:
  • Emory University — Atlanta, Georgia
Phase 1 Recruiting Academic/Other

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffu…

Sponsor: Emory University
NCT ID: NCT06624371
Sites in Georgia:
  • Arthur M Blank Hospital — Atlanta, Georgia
  • Children's Healthcare of Atlanta: Scottish Rite — Atlanta, Georgia
Phase 1 Recruiting Academic/Other

A Study of Avutometinib for People With Solid Tumor Cancers

The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06104488
Sites in Georgia:
  • Children's Healthcare of Atlanta (Data Collection Only) — Atlanta, Georgia
EARLY Phase 1 Recruiting Academic/Other

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it …

Sponsor: Emory University
NCT ID: NCT06328686
Sites in Georgia:
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Academic/Other

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the…

Sponsor: Theodore S. Johnson
NCT ID: NCT05106296
Sites in Georgia:
  • Augusta University, Georgia Cancer Center — Augusta, Georgia
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Georgia:
  • Massive Bio SYNERGY-AI site — Atlanta, Georgia
  • Massive Bio SYNERGY-AI site — Savannah, Georgia
NA Recruiting Academic/Other

Tumor Treating Fields for the Treatment of Brainstem Gliomas

This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields call…

Sponsor: Emory University
NCT ID: NCT05310448
Sites in Georgia:
  • Emory Proton Therapy Center — Atlanta, Georgia
  • Emory University/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
NA Recruiting Academic/Other

Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors

This clinical trial evaluates the impact of a research intervention of virtually supervised exercise program (RISE) on cancer-related cognitive impairment (CRCI), physical activity in adolescent and young adult (AYA) brain tumor survivors.…

Sponsor: Emory University
NCT ID: NCT06799481
Sites in Georgia:
  • Emory University Hospital — Atlanta, Georgia
NA Recruiting Academic/Other

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of t…

Sponsor: Emory University
NCT ID: NCT04278118
Sites in Georgia:
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20